miRNAs: Mediators of Erbb Family Targeted Therapy Resistance

References

• Zhang J , ZhaoH , GaoY , ZhangW . Secretory miRNAs as novel cancer biomarkers . Biochim. Biophys. Acta1826 ( 1 ), 32 – 43 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Shi X-B , TepperCG , Devere WhiteRW . Cancerous miRNAs and their regulation . Cell Cycle (TX, USA)7 ( 11 ), 1529 – 1538 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Jansson MD , LundAH . MicroRNA and cancer . Mol. Oncol.6 ( 6 ), 590 – 610 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Horikawa Y , WoodCG , YangHet al. Single nucleotide polymorphisms of microRNA-machinery genes modify the risk of renal cell carcinoma . Clin. Cancer Res.14 ( 23 ), 7956 – 7962 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Pereira DM , RodriguesPM , BorralhoPM , RodriguesCMP . Delivering the promise of miRNA cancer therapeutics . Drug Discov. Today18 ( 5–6 ), 282 – 289 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Hummel R , HusseyDJ , HaierJ . MicroRNAs: predictors and modifiers of chemo- and radiotherapy in different tumour types . Eur. J. Cancer46 ( 2 ), 298 – 311 ( 2011 ).
   Web of Science ®Google Scholar
• Slezak-Prochazka I , DurmusS , KroesenB-J , Van Den BergA . MicroRNAs, macrocontrol: regulation of miRNA processing . RNA16 ( 6 ), 1087 – 1095 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Calin GA , DumitruCD , ShimizuMet al. Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia . Proc. Natl Acad. Sci. USA99 ( 24 ), 15524 – 15529 ( 2002 ).
   PubMed Web of Science ®Google Scholar
• Croce CM . Causes and consequences of microRNA dysregulation in cancer . Nat. Rev. Genet.10 ( 10 ), 704 – 714 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Cho WCS . MicroRNAs: Potential biomarkers for cancer diagnosis, prognosis and targets for therapy . Int. J. Biochem. Cell Biol.42 ( 8 ), 1273 – 1281 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Dias F , TeixeiraAL , SantosJIet al. Renal cell carcinoma development and miRNAs: a possible link to the EGFR pathway . Pharmacogenomics14 ( 14 ), 1793 – 1803 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• He L , ThomsonJM , HemannMTet al. A microRNA polycistron as a potential human oncogene . Nature435 ( 7043 ), 828 – 833 ( 2005 ).
   PubMed Web of Science ®Google Scholar
• Hossain A , KuoMT , SaundersGF . Mir-17-5p regulates breast cancer cell proliferation by inhibiting translation of AIB1 mRNA . Mol. Cell. Biol.26 ( 21 ), 8191 – 8201 ( 2006 ).
   PubMed Web of Science ®Google Scholar
• Luqmani YA . Mechanisms of drug resistance in cancer chemotherapy . Med. Princ. Pract.14 ( Suppl. 1 ), 35 – 48 ( 2005 ).
   PubMed Web of Science ®Google Scholar
• Gerber DE . Targeted therapies: a new generation of cancer treatments . Am. Fam. Physician77 ( 3 ), 311 – 319 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Hoelder S , ClarkePA , WorkmanP . Discovery of small molecule cancer drugs: successes, challenges and opportunities . Mol. Oncol.6 ( 2 ), 155 – 176 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Huang ME , YeYC , ChenSRet al. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia . Blood72 ( 2 ), 567 – 572 ( 1988 ).
   PubMed Web of Science ®Google Scholar
• O’Brien SG , GuilhotF , LarsonRAet al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia . N. Engl. J. Med.348 ( 11 ), 994 – 1004 ( 2003 ).
   PubMed Web of Science ®Google Scholar
• Druker BJ , GuilhotF , O’BrienSGet al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia . N. Engl. J. Med.355 ( 23 ), 2408 – 2417 ( 2006 ).
   PubMed Web of Science ®Google Scholar
• Li H , YangBB . Friend or foe: the role of microRNA in chemotherapy resistance . Acta Pharmacol. Sin.34 ( 7 ), 870 – 879 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Dean M , RzhetskyA , AllikmetsR . The human ATP-binding cassette (ABC) transporter superfamily . Genome Res.11 ( 7 ), 1156 – 1166 ( 2001 ).
   PubMed Web of Science ®Google Scholar
• Huang L , FuL . Mechanisms of resistance to EGFR tyrosine kinase inhibitors . Acta Pharm. Sin. B5 ( 5 ), 390 – 401 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Shi Z , TiwariAK , ShuklaSet al. Sildenafil reverses ABCB1- and ABCG2-mediated chemotherapeutic drug resistance . Cancer Res.71 ( 8 ), 3029 – 3041 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Garofalo M , CroceCM . MicroRNAs as therapeutic targets in chemoresistance . Drug Resist. Updat.16 ( 3 ), 47 – 59 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Schechter AL , SternDF , VaidyanathanLet al. The neu oncogene: an erb-B-related gene encoding a 185,000-Mr tumour antigen . Nature312 ( 5994 ), 513 – 516 ( 1984 ).
   PubMed Web of Science ®Google Scholar
• Yarden Y , SliwkowskiMX . Untangling the ErbB signalling network . Nat. Rev. Mol. Cell Biol.2 ( 2 ), 127 – 137 ( 2001 ).
   PubMed Web of Science ®Google Scholar
• Yarden Y , PinesG . The ERBB network: at last, cancer therapy meets systems biology . Nat. Rev. Cancer12 ( 8 ), 553 – 563 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Roskoski R Jr . The ErbB/HER family of protein-tyrosine kinases and cancer . Pharmacol. Res.79 ( 0 ), 34 – 74 ( 2014 ).
   PubMedGoogle Scholar
• Teixeira AL , GomesM , MedeirosR . EGFR signaling pathway and related-miRNAs in age-related diseases: the example of miR-221 and miR-222 . Front. Genet.3 , 286 ( 2012 ).
   PubMedGoogle Scholar
• Normanno N , BiancoC , De LucaA , MaielloMR , SalomonDS . Target-based agents against ErbB receptors and their ligands: a novel approach to cancer treatment . Endocr. Relat. Cancer10 ( 1 ), 1 – 21 ( 2003 ).
   PubMed Web of Science ®Google Scholar
• Vogelstein B , PapadopoulosN , VelculescuVE , ZhouS , DiazLA , KinzlerKW . Cancer genome landscapes . Science339 ( 6127 ), 1546 – 1558 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Garraway LA , JännePA . Circumventing cancer drug resistance in the era of personalized medicine . Cancer Discov.2 ( 3 ), 214 – 226 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Hatakeyama H , ChengH , WirthPet al. Regulation of heparin-binding EGF-like growth factor by miR-212 and acquired cetuximab-resistance in head and neck squamous cell carcinoma . PLoS ONE5 ( 9 ), e12702 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Izumchenko E , ChangX , MichailidiCet al. The TGFβ–miR200–MIG6 pathway orchestrates the EMT-associated kinase switch that induces resistance to EGFR inhibitors . Cancer Res.74 ( 14 ), 3995 – 4005 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• El-Awady RA , HerziF , Al-TunaijiHet al. Epigenetics and miRNA as predictive markers and targets for lung cancer chemotherapy . Cancer Biol. Ther.16 ( 7 ), 1056 – 1070 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Nakamura K , YanoH , SchaeferE , SabeH . Different modes and qualities of tyrosine phosphorylation of Fak and Pyk2 during epithelial-mesenchymal transdifferentiation and cell migration: analysis of specific phosphorylation events using site-directed antibodies . Oncogene20 ( 21 ), 2626 – 2635 ( 2001 ).
   PubMed Web of Science ®Google Scholar
• Engelman JA , ZejnullahuK Fau , MitsudomiT , MitsudomiT Fau , SongYet al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling . Science316 ( 5827 ), 1039 – 1043 ( 2007 ).
   PubMed Web of Science ®Google Scholar
• Mellinghoff IK , CloughesyTF , MischelPS . PTEN-mediated resistance to epidermal growth factor receptor kinase inhibitors . Clin. Cancer Res.13 ( 2 ), 378 – 381 ( 2007 ).
   PubMed Web of Science ®Google Scholar
• Kamangar F , DoresGM , AndersonWF . Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world . J. Clin. Oncol.24 ( 14 ), 2137 – 2150 ( 2006 ).
   PubMed Web of Science ®Google Scholar
• Murria Estal R , Palanca SuelaS , Juan JiménezIet al. MicroRNA signatures in hereditary breast cancer . Breast Cancer Res. Treat.142 ( 1 ), 19 – 30 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Kaptain S , TanLK , ChenB . Her-2/neu and breast cancer . Diagn. Mol. Pathol.10 ( 3 ), 139 – 152 ( 2001 ).
   PubMedGoogle Scholar
• Khoshnaw SM , RakhaEA , Abdel-FatahTet al. The microRNA maturation regulator Drosha is an independent predictor of outcome in breast cancer patients . Breast Cancer Res. Treat.137 ( 1 ), 139 – 153 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Ye X , BaiW , ZhuHet al. MiR-221 promotes trastuzumab-resistance and metastasis in HER2-positive breast cancers by targeting PTEN . BMB Rep.47 ( 5 ), 268 – 273 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Gong C , YaoY , WangYet al. Up-regulation of miR-21 mediates resistance to trastuzumab therapy for breast cancer . J. Biol. Chem.286 ( 21 ), 19127 – 19137 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Johansson A-C , AnsellA , JerhammarFet al. Cancer-associated fibroblasts induce matrix metalloproteinase–mediated cetuximab resistance in head and neck squamous cell carcinoma cells . Mol. Cancer Res.10 ( 9 ), 1158 – 1168 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Price KR , CohenE . Current treatment options for metastatic head and neck cancer . Curr. Treat. Options Oncol.13 ( 1 ), 35 – 46 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Wen Y , GrandisJR . Emerging drugs for head and neck cancer . Expert Opin. Emerg. Drugs20 ( 2 ), 313 – 329 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Smith JP , PozziA , DhawanP , SinghAB , HarrisRC . Soluble HB-EGF induces epithelial-to-mesenchymal transition in inner medullary collecting duct cells by upregulating Snail-2 . Am. J. Physiol. Renal Physiol.296 ( 5 ), F957 – F965 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Yagi H , YotsumotoF , MiyamotoS . Heparin-binding epidermal growth factor-like growth factor promotes transcoelomic metastasis in ovarian cancer through epithelial–mesenchymal transition . Mol. Cancer Ther.7 ( 10 ), 3441 – 3451 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Wang F , LiuR , LeeSW , SlossCM , CougetJ , CusackJC . Heparin-binding EGF-like growth factor is an early response gene to chemotherapy and contributes to chemotherapy resistance . Oncogene26 ( 14 ), 2006 – 2016 ( 2006 ).
   PubMed Web of Science ®Google Scholar
• Jemal A , BrayF , CenterMM , FerlayJ , WardE , FormanD . Global cancer statistics . CA Cancer J. Clin.61 ( 2 ), 69 – 90 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Wozniak MB , SceloG , MullerDC , MukeriaA , ZaridzeD , BrennanP . Circulating MicroRNAs as non-invasive biomarkers for early detection of non-small-cell lung cancer . PLoS ONE10 ( 5 ), e0125026 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Yu HA , ArcilaME , RekhtmanNet al. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers . Clin. Cancer Res.19 ( 8 ), 2240 – 2247 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Gao W , LuX , LiuL , XuJ , FengD , ShuY . MiRNA-21 . Cancer Biol. Ther.13 ( 5 ), 330 – 340 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Bao L , YanY , XuCet al. MicroRNA-21 suppresses PTEN and hSulf-1 expression and promotes hepatocellular carcinoma progression through AKT/ERK pathways . Cancer Lett.337 ( 2 ), 226 – 236 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Shen H , ZhuF , LiuJet al. Alteration in Mir-21/PTEN expression modulates gefitinib resistance in non-small cell lung cancer . PLoS ONE9 ( 7 ), e103305 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Yip PY . Phosphatidylinositol 3-kinase-AKT-mammalian target of rapamycin (PI3K–AKT–mTOR) signaling pathway in non-small cell lung cancer . Transl. Lung Cancer Res.4 ( 2 ), 165 – 176 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Benedettini E , ShollLM , PeytonMet al. Met activation in non-small cell lung cancer is associated with de novo resistance to EGFR inhibitors and the development of brain metastasis . Am. J. Pathol.177 ( 1 ), 415 – 423 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Garofalo M , RomanoG , Di LevaGet al. EGFR and MET receptor tyrosine kinase-altered microRNA expression induces tumorigenesis and gefitinib resistance in lung cancers . Nat. Med.18 ( 1 ), 74 – 82 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Wang YS , WangYH , XiaHP , ZhouSW , Schmid-BindertG , ZhouCC . MicroRNA-214 regulates the acquired resistance to gefitinib via the PTEN/AKT pathway in EGFR-mutant cell lines . Asian Pac. J. Cancer Prev.13 ( 1 ), 255 – 260 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Yamasaki F , JohansenMJ , ZhangDet al. Acquired resistance to erlotinib in A-431 epidermoid cancer cells requires down-regulation of MMAC1/PTEN and up-regulation of phosphorylated Akt . Cancer Res.67 ( 12 ), 5779 – 5788 ( 2007 ).
   PubMed Web of Science ®Google Scholar
• Zhang Z , LeeJC , LinLet al. Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer . Nat. Genet.44 ( 8 ), 852 – 860 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Wang Y , XiaH , ZhuangZ , MiaoL , ChenX , CaiH . Axl-altered microRNAs regulate tumorigenicity and gefitinib resistance in lung cancer . Cell Death Dis.5 ( 5 ), e1227 ( 2014 ).
   PubMedGoogle Scholar
• Bang Y-J , Van CutsemE , FeyereislovaAet al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a Phase 3, open-label, randomised controlled trial . Lancet376 ( 9742 ), 687 – 697 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Lee JY , HongM , KimSTet al. The impact of concomitant genomic alterations on treatment outcome for trastuzumab therapy in HER2-positive gastric cancer . Sci. Rep.5 , 9289 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Eto K , IwatsukiM , WatanabeMet al. The microRNA-21/PTEN pathway regulates the sensitivity of HER2-positive gastric cancer cells to trastuzumab . Ann. Surg. Oncol.21 ( 1 ), 343 – 350 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Ross JS , FletcherJA . The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy . Stem Cells16 ( 6 ), 413 – 428 ( 1998 ).
   PubMed Web of Science ®Google Scholar
• Ross JS , FletcherJA , BloomKJet al. Targeted therapy in breast cancer: The HER-2/neu gene and protein . Mol. Cell. Proteomics3 ( 4 ), 379 – 398 ( 2004 ).
   PubMed Web of Science ®Google Scholar
• Khoshnaw SM , RakhaEA , Abdel-FatahTMet al. Loss of Dicer expression is associated with breast cancer progression and recurrence . Breast Cancer Res. Treat.135 ( 2 ), 403 – 413 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Teixeira A , FerreiraM , SilvaJet al. Higher circulating expression levels of miR-221 associated with poor overall survival in renal cell carcinoma patients . Tumor Biol.35 ( 5 ), 4057 – 4066 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Nahta R , YuanLXH , ZhangB , KobayashiR , EstevaFJ . Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells . Cancer Res.65 ( 23 ), 11118 – 11128 ( 2005 ).
   PubMed Web of Science ®Google Scholar
• Ye X-M , ZhuH-Y , BaiW-Det al. Epigenetic silencing of miR-375 induces trastuzumab resistance in HER2-positive breast cancer by targeting IGF1R . BMC Cancer14 , 134 – 134 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Nagata Y , LanK-H , ZhouXet al. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients . Cancer Cell6 ( 2 ), 117 – 127 ( 2004 ).
   PubMed Web of Science ®Google Scholar
• Corcoran C , RaniS , BreslinSet al. miR-630 targets IGF1R to regulate response to HER-targeting drugs and overall cancer cell progression in HER2 over-expressing breast cancer . Mol. Cancer13 , 71 – 71 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Haggar FA , BousheyRP . Colorectal cancer epidemiology: incidence, mortality, survival, and risk factors . Clin. Colon Rectal Surg.22 ( 4 ), 191 – 197 ( 2009 ).
   PubMedGoogle Scholar
• Siena S , Sartore-BianchiA , Di NicolantonioF , BalfourJ , BardelliA . Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer . J. Natl Cancer Inst.101 ( 19 ), 1308 – 1324 ( 2009 ).
   PubMedGoogle Scholar
• Karapetis CS , Khambata-FordS , JonkerDJet al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer . N. Engl. J. Med.359 ( 17 ), 1757 – 1765 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Ng EKO , ChongWWS , JinHet al. Differential expression of microRNAs in plasma of patients with colorectal cancer: a potential marker for colorectal cancer screening . Gut58 ( 10 ), 1375 – 1381 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Ragusa M , MajoranaA , StatelloLet al. Specific alterations of microRNA Transcriptome and global network structure in colorectal carcinoma after cetuximab treatment . Mol. Cancer Ther.9 ( 12 ), 3396 – 3409 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Simons M , RaposoG . Exosomes – vesicular carriers for intercellular communication . Curr. Opin. Cell Biol.21 ( 4 ), 575 – 581 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Mathivanan S , JiH , SimpsonRJ . Exosomes: extracellular organelles important in intercellular communication . J. Proteomics73 ( 10 ), 1907 – 1920 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Simpson RJ , JensenSS , LimJWE . Proteomic profiling of exosomes: current perspectives . Proteomics8 ( 19 ), 4083 – 4099 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Sato-Kuwabara Y , MeloSA , SoaresFA , CalinGA . The fusion of two worlds: non-coding RNAs and extracellular vesicles – diagnostic and therapeutic implications (Review) . Int. J. Oncol.46 ( 1 ), 17 – 27 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Skog J , WurdingerT , Van RijnSet al. Glioblastoma microvesicles transport RNA and protein that promote tumor growth and provide diagnostic biomarkers . Nat. Cell Biol.10 ( 12 ), 1470 – 1476 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Rabinowits G , Gerçel-TaylorC , DayJM , TaylorDD , KloeckerGH . Exosomal microRNA: a diagnostic marker for lung cancer . Clin. Lung Cancer10 ( 1 ), 42 – 46 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Salido-Guadarrama I , Romero-CordobaS , Peralta-ZaragozaO , Hidalgo-MirandaA , Rodríguez-DorantesM . MicroRNAs transported by exosomes in body fluids as mediators of intercellular communication in cancer . Onco Targets Ther.7 , 1327 – 1338 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Kalra H , AddaCG , LiemMet al. Comparative proteomics evaluation of plasma exosome isolation techniques and assessment of the stability of exosomes in normal human blood plasma . Proteomics13 ( 22 ), 3354 – 3364 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Suntres ZE , SmithMG , Momen-HeraviFet al. Therapeutic uses of exosomes . Exosomes Microvesicles1 ( 5 ), 33 – 40 ( 2013 ).
   Google Scholar
• Johnson SM , GulhatiPaT , ArrietaIet al. Curcumin inhibits proliferation of colorectal carcinoma by modulating Akt/mTOR signaling . Anticancer Res.29 ( 8 ), 3185 – 3190 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• James Graham Brown Cancer Center; University of Louisville . Study investigating the ability of plant exosomes to deliver curcumin to normal and colon cancer tissue . NLM identifier: NCT01294072https://clinicaltrials.gov/show/NCT01294072 .
   Google Scholar
• Liu K , ZhangC , LiTet al. Let-7a inhibits growth and migration of breast cancer cells by targeting HMGA1 . Int. J. Oncol.46 ( 6 ), 2526 – 2534 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Ohno S-I , TakanashiM , SudoKet al. Systemically injected exosomes targeted to EGFR deliver antitumor microRNA to breast cancer cells . Mol. Ther.21 ( 1 ), 185 – 191 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Ren J , HeW , ZhengL , DuanH . From structures to functions: insights into exosomes as promising drug delivery vehicles . Biomater. Sci. doi:10.1039/C5BM00583C ( 2016 ) ( Epub ahead of print ).
   Web of Science ®Google Scholar